You just read:

Analysis of Over 1000 Psoriatic Arthritis (PsA) Patients Reveals Large Candidate Pool for Pfizer's Xeljanz, BMS' Orencia, and Eli Lilly's Taltz

News provided by

Spherix Global Insights

Sep 26, 2017, 04:00 ET